• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

SEQSTER and PatientsLikeMe Launch National Rare Disease Study

Share:

October 11, 2022

What You Should Know:

– PatientsLikeMe and SEQSTER announced a collaboration to launch one of the first rare-disease studies focused on Alpha-1 Antitrypsin Deficiency (AATD) – a rare genetic condition occurring in approximately 1/3500 people.

– AATD is a rare genetic condition occurring in approximately 1/3500 people. It is characterized by low levels of the alpha-1 antitrypsin protein, leading AATD patients to be very susceptible to lung and/or liver disease. Although AATD can be diagnosed through genetic testing or through AATD serum level, many cases of AATD are undiagnosed, with some studies suggesting up to 90% of patients may be undiagnosed or misdiagnosed.

– Participants living with AATD now can consent, share, and engage with all of their data in one place, leading to a seamless longitudinal patient journey.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Source: Hitconsultant

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Season Health, Geisinger, Commonspirit Health, Cricket Health Launches Anchor Partnerships to Scale Food as Medicine InitiativesSeason Health, Geisinger, Commonspirit Health, Cricket Health Launches Anchor Partnerships to Scale Food as Medicine Initiatives
  • Former Kaiser Permanente Cto Mike Sutten Joins Innovaccer as Chief Digital OfficerFormer Kaiser Permanente Cto Mike Sutten Joins Innovaccer as Chief Digital Officer
  • X4 Pharmaceuticals Completes Merger with ArsanisX4 Pharmaceuticals Completes Merger with Arsanis
  • UCSD Partners with Cofactor Genomics to Improve Head and Neck Cancer OutcomesUCSD Partners with Cofactor Genomics to Improve Head and Neck Cancer Outcomes
  • AstraZeneca sells older asthma, rhinitis drugs for $350 millionAstraZeneca sells older asthma, rhinitis drugs for $350 million
  • Biodesix to Acquire Oncimmune in the United StatesBiodesix to Acquire Oncimmune in the United States
  • PharmaDrug Inc. Enters Definitive Agreement to Acquire SecureDose SyntheticsPharmaDrug Inc. Enters Definitive Agreement to Acquire SecureDose Synthetics
  • Mark Cuban Cost Plus Drug Company Partners with Diabetes Management PlatformMark Cuban Cost Plus Drug Company Partners with Diabetes Management Platform

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications